Life Choices

CML survivor Erin Zammett Ruddy wants a baby. The trade-off may be her health.

KATHY LATOUR
PUBLISHED: 1:00 AM, MON APRIL 9, 2007
Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
When Erin Zammett received her journalism degree in May 2000, she had already planned her next step: a course that would give her a job-hunting edge in New York City’s competitive publishing world.

By the end of the course, the University of Tennessee grad had been approached by one of the speakers, an editor at Glamour magazine, impressed not only with Zammett’s 3.9 college GPA, but also with the fact that the sassy, 5-foot-9-inch Zammett had been the first woman accepted as an intern by Playboy magazine.

Zammett also looked the part of a Glamour editor. As an athlete she allowed herself only infrequent, age-appropriate overindulging, focusing on building not only an athlete’s body, but one that would someday carry a child.

At the same time that Zammett was becoming an “it girl” on the East Coast, oncologist and researcher Brian Druker, MD, of Oregon Health & Science University Cancer Institute in Portland, was watching seven years of research come to fruition.

Since 1993 Druker had been working on a targeted therapy for cancer—a new approach to cancer treatment that researchers saw as an avenue to make cancer a manageable, chronic disease by shutting down one or more of the mechanisms that tell a cell to divide. Across the country, researchers such as Druker had been exploring myriad ways to interrupt cell division. Many of them reached dead ends after being outwitted by the body’s intricate ability to safeguard cell growth.

Druker’s focus was a compound that would shut down a family of enzymes that prompted growth in a number of cancers, one of which was chronic myeloid leukemia, or CML, a cancer of the bone marrow that causes rapid growth of immature white blood cells. People with CML can live for years without being aware of its presence until the cancer hits high gear, filling the body with leukemia cells. When Druker’s drug showed success, it finally offered an option for CML patients other than a bone marrow transplant, the only treatment that approached a cure for the cancer. Known as the treatment that might kill you before the disease does, bone marrow transplant requires hospitalization and extensive chemotherapy to kill the leukemia cells before the patient is “rescued” with new bone marrow. It is a difficult treatment and leaves the patient sterile.

Druker’s drug would be taken daily in pill form and have few side effects for the patients whose cancer could be controlled by the minimal dosage. As it showed more and more promise, the new drug was moved through clinical trials quickly. By 1998 phase I trials had begun, showing results more remarkable than expected and leading quickly to phase II and phase III trials in order to get the drug to those who had relapsed after bone marrow transplants. 

As Druker’s compound moved through phase I and phase II clinical trials, Zammett was firmly ensconced in New York City with a great job, an apartment, and her family only a few train stops away on Long Island.

From an early age Zammett had made decisions with clarity and determination, planning for a future that she envisioned would combine a successful career and a large, loving family like her own.

Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
Special Feature
Share Your Art
Related Articles
Then and Now: Reflections for a New Year of Survivorship After Cancer
Doing a little reflection about where I've been and how far I've come is just as important as making resolutions.
Grudge Match: My Journey With Chronic Myeloid Leukemia
Why does a cancer diagnosis always come down to being a winner or a loser?
FDA Approves Extended Therapy With Arzerra for Chronic Lymphocytic Leukemia
The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.
Related Videos
Kevin C. Oeffinger on Tailoring Survivorship Care
We spoke with Oeffinger during the 2016 Cancer Survivorship Symposium in mid-January.
Mary McCabe on the Need for Personalized Survivorship Care
McCabe addressed this topic and others in her talk, "Models of Delivery" at the 2016 Cancer Survivorship Symposium in San Francisco.
William G. Wierda on the Treatment of CLL
CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.
$auto_registration$